FARON:HEL
Faron Pharmaceuticals Oy
€0.40
arrow_downward
-1.83%(-0.0075) 1D
Oct 20, 5:55:41 PM GMT+3 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARON...
Open
€0.41
High
€0.41
Low
€0.40
Mkt. cap
72.18M
Avg. vol.
715.11K
Volume
466.49K
52-wk high
€2.31
52-wk low
€0.39
Shares outstanding
202.88M
No. of employees
36
Open
€0.41
High
€0.41
Low
€0.40
Mkt. cap
72.18M
Avg. vol.
715.11K
Volume
466.49K
52-wk high
€2.31
52-wk low
€0.39
Shares outstanding
202.88M
No. of employees
36
News stories
From web sources and news partners
Investing.com India
·
1 day ago
Faron to present final melanoma survival data at ESMO congress By Investing.com
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy